Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 30 of 92 for:    high | Recruiting, Not yet recruiting, Available Studies | "Metabolic Syndrome X"

New Insights Into the Metabolic Syndrome: the Role of Alpha Defensin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03469115
Recruitment Status : Not yet recruiting
First Posted : March 19, 2018
Last Update Posted : March 19, 2018
Sponsor:
Information provided by (Responsible Party):
Hillel Yaffe Medical Center

Brief Summary:
The purpose of this study is to find out if there is a connection between a higher level of peptide alpha defensin in blood serum with the metabolic profile of adolescents aged 13-17.

Condition or disease Intervention/treatment Phase
Metabolic Syndrome Diagnostic Test: Serum blood Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Adolescents aged 13-17 will be divided into two groups according to BMI (body mass index)
Masking: None (Open Label)
Primary Purpose: Screening
Official Title: New Insights Into the Metabolic Syndrome: the Role of Alpha Defensin
Estimated Study Start Date : March 2018
Estimated Primary Completion Date : September 2019
Estimated Study Completion Date : September 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: BMI above 95%
Serum blood will be taken from obese youths with suspected metabolic syndrome
Diagnostic Test: Serum blood
Serum blood test for laboratory analysis to determine level of alpha defensin

Active Comparator: BMI below 3%
Serum blood will be taken from slim youths
Diagnostic Test: Serum blood
Serum blood test for laboratory analysis to determine level of alpha defensin




Primary Outcome Measures :
  1. Alpha defensin level [ Time Frame: 2 hours ]
    Alpha defensin level above 12ng/microliter



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   13 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Youths with metabolic syndrome (BMI above 95%)
  • Youths with BMI below 3%

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03469115


Contacts
Layout table for location contacts
Contact: Eias Kassem, MD 972-50-6246882 eiask@hy.health.gov.il

Locations
Layout table for location information
Israel
Hille Yaffe Medical Center Not yet recruiting
Hadera, Israel, 38100
Contact: Eias Kassem, MD       eiask@hy.health.gov.il   
Sponsors and Collaborators
Hillel Yaffe Medical Center
Investigators
Layout table for investigator information
Principal Investigator: Eias Kassem, MD Hillel Yaffe Medical Center

Layout table for additonal information
Responsible Party: Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier: NCT03469115     History of Changes
Other Study ID Numbers: HYMC-15-18
First Posted: March 19, 2018    Key Record Dates
Last Update Posted: March 19, 2018
Last Verified: March 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Metabolic Syndrome
Syndrome
Disease
Pathologic Processes
Insulin Resistance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Defensins
alpha-Defensins
Anti-Infective Agents